PARD6B

Across TCGA pan-cancer cohorts, PARD6B RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated PARD6B data layer compared with 5 for mutation status and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PARD6B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PARD6B expression acts as an unfavorable survival marker, although some lineages such as KIRC and BRCA show a favorable association.

LIHC, KIRC, and BRCA are the cancer types where PARD6B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.466	0.615	<.001	101	view →
KIRC	OS	Tertile	All	0.717	0.532	<.001	77	view →
BRCA	DFS	Median	III,IV	0.881	0.715	<.001	71	view →
MESO	OS	Quartile	All	0.454	0.214	.003	31	view →
UCEC	DFS	Tertile	All	0.562	0.836	<.001	26	view →
PAAD	OS	Quartile	All	0.305	0.584	.008	22	view →
LGG	OS	Quartile	All	0.233	0.609	<.001	21	view →
SKCM	DFS	Median	II,III,IV	0.290	0.155	.002	21	view →
ACC	OS	Quartile	III,IV	0.804	0.371	.009	19	view →
OV	DFS	Median	II,III,IV	0.496	0.581	.012	18	view →
CHOL	DFS	Median	IV	0.251	0.794	.010	12	view →
READ	DFS	Quartile	III,IV	1.000	0.236	.007	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

PARD6B–LIHC (DFS)

Open the LIHC breakdown →